RecruitingNCT06796062
Psilocybin added to methadone for opioid use disorder
Medication studyAges 18–65United StatesAddiction
Understand this study
Who could participate?
Listed age limits: 18 years to 65 years.
- Listed locations
- Albuquerque and 4 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: December 17, 2025
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 480
- Sponsor
- NYU Langone Health
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT06796062
- Official title
Show the full official title
A Phase 2 Trial of Psilocybin as an Adjunctive Treatment for OUD Patients Who Continue to Use Illicit Opioids Despite Adherence to Methadone Treatment
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Albuquerque · Brooklyn · New York
1 more locations
- The Bronx
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is NYU Langone Health.
Does this study involve medication?
Yes. The study involves medication, including Psilocybin.
Who can participate?
Listed age limits: 18 years to 65 years.
Is this study still recruiting?
The registry lists this study as recruiting.
